(Q34471224)

2 August 2017

1 reference

title

Review of treatment options for lyme borreliosis (English)

1 reference

2 August 2017

0 references

Taylor RS

1

1 reference

PubMed ID

16315580

2 August 2017

Simpson IN

series ordinal

2

1 reference

2 August 2017

1 September 2005

1 reference

2 August 2017

Journal of Chemotherapy

1 reference

2 August 2017

17 Suppl 2

1 reference

2 August 2017

3-16

1 reference

Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum

2 August 2017

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Lyme borreliosis: from infection to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Lyme disease (Lyme borreliosis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Detection of Borrelia burgdorferi DNA by Polymerase Chain Reaction in Synovial Fluid from Patients with Lyme Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Current and novel therapies for Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

The emergence of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Chronic neurologic manifestations of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Evaluation of study patients with Lyme disease, 10-20-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparison of Cefuroxime Axetil and Doxycycline in the Treatment of Early Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparison of azithromycin and doxycycline in the treatment of erythema migrans

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Successful treatment of Lyme encephalopathy with intravenous ceftriaxone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Ceftriaxone in the treatment of Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Neurocognitive abnormalities in children after classic manifestations of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Failure of treatment with cephalexin for Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Diagnosis, treatment, and prevention of Lyme disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

New Chemotherapeutic Approaches in the Treatment of Lyme Borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Cefotaxime versus penicillin in the late stage of Lyme disease--prospective, randomized therapeutic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

A cost-of-illness study of Lyme disease in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-2.3

10.1179/JOC.2005.17.SUPPLEMENT-2.3

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

16315580